symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
NRBO,0.464,-0.798866,224782,17831149,0,0.361-14.3,-0.006,"NeuroBo Pharmaceuticals, Inc.",USD,0001638287,US64132R1077,64132R107,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.neurobopharma.com,"NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.",Mr. Hyung-Heon  Kim,Healthcare,US,2,857 702 9600,200 Berkeley Street,Boston,MA,02116,1.46076,2.27046,https://financialmodelingprep.com/image-stock/NRBO.png,2016-08-05,False,False,True,False,False
